Food Allergies

• Recognize and Respond to Anaphylaxis
• FARE (Food Allergy Research & Education) Resources
• Common Allergens
• Understanding Food Labels
• It’s a Disease, Not a Diet: A documentary about life with food allergies
• Children With Food Allergies
• Living with Food Allergies: Preparing for College
• Omalizumab for the Treatment of Multiple Food Allergies
• Omalizumab Prescribing Information
• Peanut Oral Immunotherapy Prescribing Information
• Clinical Burden of Food Allergies: Insights from the FARE Patient Registry
• Mental Health Burden of Food Allergies: Insights from Patients and Their Caregivers from FARE Patient Registry
• Food Allergies: National Institute of Allergy and Infectious Diseases
• Food Allergy Information from the American College of Allergy, Asthma & Immunology
• Kids With Food Allergies
• FARE powered by Sifter Shopping Tool for Food Allergy Needs
• Food allergy, mechanisms, diagnosis and treatment: Innovation through a multi-targeted approach
• FDA: Food Allergies
• Managing food allergy: GA2LEN guideline 2022

Asthma

• Dupilumab Prescribing Information
• Tezepelumab Prescribing Information
• Tezepelumab in Adults and Adolescents with Severe, Uncontrolled Asthma
• Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines – recommendations on the use of biologicals in severe asthma
• Dupilumab in Children with Uncontrolled Moderate-to-Severe Asthma
• 2022 GINA Pocket Guide for Asthma Management and Prevention (for Adults and Children Older Than 5 Years)
• 2022 GINA Main Report: Global Strategy for Asthma Management and Prevention
• American Lung Association: Severe Asthma
• Advances and recent developments in asthma in 2020
• Asthma biologics: Comparing trial designs, patient cohorts and study results
• Mepolizumab Prescribing Information
• National Jewish Health Inhaler Instructional Videos

Chronic Spontaneous Urticaria (CSU)

• Current and Emerging Therapies for Chronic Spontaneous Urticaria: A Narrative Review
• Chronic spontaneous urticaria: Focus on pathophysiology to unlock treatment advances
• Dupilumab Improves Urticaria Activity And Quality Of Life In Patients With Chronic Spontaneous Urticaria (CSU)
• Dupilumab Significantly Reduces Itch and Hives in Patients With Chronic Spontaneous Urticaria: Results From a Phase 3 Trial (LIBERTY-CSU CUPID Study A)
• Remibrutinib demonstrates favorable safety profile and sustained efficacy in chronic spontaneous urticaria over 52 weeks
• Urticaria
• Omalizumab Re-Treatment and Step-Up in Patients with Chronic Spontaneous Urticaria: OPTIMA Trial
• Remibrutinib, a novel BTK inhibitor, demonstrates promising efficacy and safety in chronic spontaneous urticaria
• Dupilumab Efficacy In Patients With Chronic Spontaneous Urticaria By Ige Level: Liberty-CSU Cupid Study A
• Novel biologics for treatment of chronic spontaneous urticaria
• Dupilumab: A Review of Present Indications and Off-Label Uses
• Remibrutinib (LOU064): A selective potent oral BTK inhibitor with promising clinical safety and pharmacodynamics in a randomized phase I trial
• Fenebrutinib in H1 antihistamine-refractory chronic spontaneous urticaria: a randomized phase 2 trial
• Total IgE as a Marker for Chronic Spontaneous Urticaria
• Chronic Idiopathic Urticaria
• Chronic spontaneous urticaria: Focus on pathophysiology to unlock treatment advances
• The international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria
• Patient education: Hives (urticaria) (Beyond the Basics)

Acute Coronary Syndrome

• Acute Myocardial Infarction Toolkit
• Heart Disease: Resources for Individuals and Patients
• Acute coronary syndromes
• 2020 ESC NSTE-ACS Guidelines: Evolving Approaches and Recommendations
• 2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guideline for the Evaluation and Diagnosis of Chest Pain: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines

Atherothrombosis

• 2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack
• Coagulation factor Xa (recombinant), inactivated-zhzo Prescribing Information
• 2020 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants: A Report of the American College of Cardiology Solution Set Oversight Committee
• Management of bleeding in patients receiving direct oral anticoagulants

Cardiac Imaging

• 2021AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guideline for the Evaluation and Diagnosis of Chest Pain
• Selecting the optimal cardiac stress test

Dyslipidemia

• Impact of Bempedoic Acid on Total Cardiovascular Events: A Prespecified Analysis of the CLEAR Outcomes Randomized Clinical Trial
• An “Inclisiran First” Strategy vs Usual Care in Patients With Atherosclerotic Cardiovascular Disease
• ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways
• HPS3/TIMI55-REVEAL: Long-term Safety and Efficacy of Anacetrapib
• ROSE Study: Obicetrapib and High-Intensity Statin Therapy
• Cholesteryl ester transfer protein inhibitors: from high-density lipoprotein cholesterol to low-density lipoprotein cholesterol lowering agents?
• Bempedoic Acid for LDL-C Lowering: What Do We Know?
• Heart Disease and Stroke Statistics—2021 Update
• Identification of female-specific risk enhancers throughout the lifespan of women to improve CVD prevention
• Identification of female-specific risk enhancers throughout the lifespan of women to improve cardiovascular disease prevention
• Prescribing Information for Alirocumab
• ACC Statin Intolerance Tool
• Cholesterol Tools and Resources

Familial Chylomicronemia Syndrome (FCS)

• Qualitative development of the PROMIS Profile v1.0-Familial Chylomicronemia Syndrome (FCS) 28
• Understanding FCS – for Patients
• About FCS
• 2015-2020 Dietary Guidelines

Familial Hypercholesterolemia (FH)

• Diagnostic Criteria for Familial Hypercholesterolemia
• Familial Hypercholesterolemia: Cardiovascular Risk Stratification and Clinical Management

Heart Failure (HF)

• Optimal Background Pharmacological Therapy for Heart Failure Patients in Clinical Trials: JACC Review Topic of the Week
• Effect of Empagliflozin on Worsening Heart Failure Events in Patients With Heart Failure and Preserved Ejection Fraction: EMPEROR-Preserved Trial
• Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction: Results of DAPA-HF
• Reverse Cardiac Remodeling Following Initiation of Sacubitril/Valsartan in Patients With Heart Failure With and Without Diabetes
• 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines
• Clinical Outcomes and Response to Vericiguat According to Index Heart Failure Event: Insights From the VICTORIA Trial
• Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction
• A Standardized and Comprehensive Approach to the Management of Cardiogenic Shock
• Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure
• Heart Failure: Patient Education

Hypertension

• CDC Facts About Hypertension
• Harmonization of the American College of Cardiology/American Heart Association and European Society of Cardiology/European Society of Hypertension Blood Pressure/Hypertension Guidelines: Comparison, Reflections, and Recommendations
• High Blood Pressure Information for Patients
• Treatment of resistant hypertension
• Million Hearts® Hypertension Control: Action Steps for Clinicians

Hypertriglyceridemia

• Comparative Reductions in Investigator-Reported and Adjudicated Ischemic Events in REDUCE-IT
• Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: a prospective, placebo-controlled randomized trial (EVAPORATE): interim results
• 2021 ACC Expert Consensus Decision Pathway on the Management of ASCVD Risk Reduction in Patients With Persistent Hypertriglyceridemia: A Report of the American College of Cardiology Solution Set Oversight Committee
• REDUCE-IT: Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial. AHA 2018.
• Fish and Omega-3 Fatty Acids

Hypertrophic Cardiomyopathy (HCM)

• Provider Tools: AHA HCM Educational Resources
• Partnership Between Primary Care and Centers of Excellence for HCM
• Provider Tools: Genetic Testing and Counseling for HCM
• Systematic Review of Current Diagnostic and Treatment Methods for HCM
• Talking With Patients About Hypertrophic Cardiomyopathy
• 2024 AHA/ACC/Multisociety Guideline for the Management of HCM
• Mavacamten Prescribing Information
• Mavacamten REMS (Risk Evaluation and Mitigation Strategy)
• Mavacamten Treatment for Symptomatic Obstructive Hypertrophic Cardiomyopathy
• VALOR-HCM: A Study to Evaluate Mavacamten in Adults With Symptomatic Obstructive HCM Who Are Eligible for Septal Reduction Therapy
• Risk Stratification in HCM
• Diagnosis and Evaluation of Hypertrophic Cardiomyopathy: JACC State-of-the-Art Review
• Associations of Race and Ethnicity With Presentation and Outcomes of Hypertrophic Cardiomyopathy
• Patient Information: Hypertrophic Cardiomyopathy (HCM)
• Hypertrophic Cardiomyopathy Association (HCMA)
• Patient Information: Hypertrophic Cardiomyopathy (HCM)
• Encouraging Shared Decision Making in HCM
• Patient Info: HCM Action Plan
• Patient Info: HCM Fact Sheets
• Patient Info: HCM Genetic Testing
• Patient Info: Hypertrophic Cardiomyopathy

Lipoprotein (a) [Lp(a)]

• A Focused Update to the 2019 NLA Scientific Statement on Use of Lipoprotein(a) in Clinical Practice
• Patient Resource: What is Lipoprotein(a)?
• Patient Resource: Treating High Lp(a)
• Assessing Risk: Infographic on Lp(a) Screening
• Emerging RNA Therapeutics to Lower Blood Levels of Lp(a)
• Treatment and prevention of lipoprotein(a)-mediated cardiovascular disease

Venous Thromboembolism (VTE)

• American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism
• Antithrombotic Therapy for VTE Disease: Second Update of the CHEST Guideline and Expert Panel Report
• What is Venous Thromboembolism (VTE)?
• Wells’ Criteria for Pulmonary Embolism

Alopecia

• National Alopecia Areata Foundation: Patient Resources
• Alopecia Areata: Current Treatments and New Directions
• Janus kinase inhibitors for alopecia areata
• Treatment Options for Alopecia Areata in Children and Adolescents
• Ritlecitinib Prescribing Information
• Efficacy and safety of ritlecitinib in adolescents with alopecia areata: Results from the ALLEGRO phase 2b/3 randomized, double-blind, placebo-controlled trial
• Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b-3 trial
• Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program
• Defining Severity in Alopecia Areata: Current Perspectives and a Multidimensional Framework
• Development of the alopecia areata scale for clinical use: Results of an academic-industry collaborative effort

Atopic dermatitis

• Which Clinical Measurement Tools for Atopic Dermatitis Severity Make the Most Sense in Clinical Practice?
• Prevalence and burden of atopic dermatitis involving the head, neck, face, and hand
• New Perspectives in the Management of Chronic Hand Eczema: Lessons from Pathogenesis
• Validation of the Investigator Global Assessment of Chronic Hand Eczema (IGA–CHE): a new clinician reported outcome measure of CHE severity
• Efficacy and Safety of Dupilumab in the Treatment of Hand Eczema
• Dupilumab treatment improves signs, symptoms, quality of life, and work productivity in patients with atopic hand and foot dermatitis
• Atopic hand dermatitis
• Atopic Dermatitis: Diagnosis and Treatment
• Emerging Systemic Treatments for Atopic Dermatitis
• Therapeutic education in atopic dermatitis
• Towards More Shared Decision Making in Dermatology: Develop­ment of Evidence-based Decision Cards for Psoriasis and Atopic Eczema Treatments
• Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis and Prior Use of Systemic Non-Steroidal Immunosuppressants: Analysis of Four Phase 3 Trials
• Dupilumab Provides Clinically Meaningful Responses in Children Aged 6–11 Years with Severe Atopic Dermatitis: Post Hoc Analysis Results from a Phase 3 Trial
• Atopic Dermatitis: Patient Materials

Facial Aesthetics

• FDA Approval: Restylane® Contour – P140029/S032

Pemphigus Vulgaris (PV)

• Rituximab is an effective treatment in patients with pemphigus vulgaris and demonstrates a steroid-sparing effect
• Rituximab versus Mycophenolate Mofetil in Patients with Pemphigus Vulgaris
• Pemphigus Vulgaris

Prurigo Nodularis

• Prurigo Nodularis Signs and Symptoms – AAD Patient Resource
• 2022 Prurigo Nodularis Facts, Symptoms, Testing and Treatment – JAMA Patient Resource
• 2022 JAAD Health-related Quality of Life and Economic Burden of Prurigo Nodularis
• Dupilumab in patients with prurigo nodularis: two randomized, double-blind, placebo-controlled phase 3 trials (PRIME and PRIME2)
• Efficacy and safety of vixarelimab, a human monoclonal oncostatin M receptor β antibody, in moderate-to-severe prurigo nodularis: a randomised, double-blind, placebo-controlled, phase 2a study
• Efficacy and safety of oral nalbuphine extended release in prurigo nodularis: results of a phase 2 randomized controlled trial with an open-label extension phase
• Trial of Nemolizumab in Moderate-to-Severe Prurigo Nodularis
• Nemolizumab efficacy in prurigo nodularis: onset of action on itch and sleep disturbances
• Psychiatric Comorbidity and the Impact of Socioeconomic Status in Prurigo Nodularis
• Immunotargets and Immunotherapy for Prurigo Nodularis
• 2021 United States Expert Panel Consensus on the Diagnosis and Management of Prurigo Nodularis
• Pathophysiology, Diagnosis and Pharmacologic Treatment of Prurigo Nodularis
• Etiology, Clinical Diagnosis, Treatment Planning and Patient Education for Prurigo Nodularis

Psoriasis

• Time to Relapse After Discontinuing Systemic Treatment for Psoriasis: A Systematic Review
• Comparison of Biologics and Oral Treatments for Plaque Psoriasis: A Meta-analysis
• Psoriatic Disease Information for Parents/Caregivers
• Treatments for Psoriatic Disease – For Patients
• Understanding Psoriatic Disease – For Patients
• Psoriasis Clinical Guideline from the American Academy of Dermatology
• National Psoriasis Foundation
• Psoriasis Q & A – For Patients

Diabetes Mellitus

• Diabetes-Related Macular Edema
• CDC Managing Blood Sugar
• AFP Publications: Type 2 Diabetes
• Guidelines for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes: JACC Guideline Comparison
• The Links Between Sleep Duration, Obesity and Type 2 Diabetes Mellitus
• Obesity Management as a Primary Treatment Goal for Type 2 Diabetes: Time to Reframe the Conversation
• Standards of Medical Care in Diabetes—2022
• Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes
• Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes—2022
• New Decade, New FDA Guidance for Diabetes Drug Development
• Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes
• 2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes
• AACE Diabetes Resource Center
• Diabetic Retinopathy: A Position Statement by the ADA
• Family Practice Management Toolbox: Diabetes
• Diabetes and You: All Medicines Matter!
• Advanced Insulin Management: Using Insulin-to-Carb Ratios and Correction Factors
• Living with Diabetes

Acromegaly

• Acromegaly Patient Information
• A Comprehensive Review of Four Clinical Practice Guidelines of Acromegaly
• Results From the Phase 3, Randomized, Double-Blind, Placebo-Controlled OPTIMAL Study of Oral Octreotide Capsules in Adult Patients with Acromegaly

Osteoporosis

• Management of osteoporosis in postmenopausal women: the 2021 position statement of The North American Menopause Society
• Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society Guideline Update
• Overview of the management of osteoporosis in postmenopausal women
• NIH Handout on Health: Osteoporosis – Patient Handout

Chronic Cough

• Cough hypersensitivity and chronic cough
• The current and emerging treatment landscape for chronic cough
• Efficacy and safety of gefapixant, a P2X₃ receptor antagonist, in refractory chronic cough and unexplained chronic cough (COUGH-1 and COUGH-2): results from two double-blind, randomised, parallel-group, placebo-controlled, phase 3 trials
• Improvements in Objective and Subjective Measures of Chronic Cough with Gefapixant: A Pooled Phase 3 Efficacy Analysis of Predefined Subgroups
• Healthcare utilization and costs in chronic cough
• Incidence and Prevalence of Cough in a Rural Health System: A 20-Year Study
• Chronic cough: new insights and future prospects
• On Chronic Cough Diagnosis, Classification, and Treatment
• Characterization of Patients With Refractory or Unexplained Chronic Cough Participating in a Phase 2 Clinical Trial of the P2X3-Receptor Antagonist Gefapixant
• Understanding the Foundations of Chronic Cough
• American Lung Association: Chronic Cough Resources and Videos
• European Respiratory Society Guidelines on the Diagnosis and Treatment of Chronic Cough in Adults and Children
• Management of chronic refractory cough in adults
• Gefapixant, a P2X3 receptor antagonist, for the treatment of refractory or unexplained chronic cough: a randomised, double-blind, controlled, parallel-group, phase 2b trial
• P2X3-Receptor Antagonists as Potential Antitussives: Summary of Current Clinical Trials in Chronic Cough

Pain Management

• CDC Clinical Practice Guideline for Prescribing Opioids for Pain — United States, 2022

Peyronie’s Disease

• A clinical pathway for the management of Peyronie’s disease: integrating clinical guidelines from the International Society of Sexual Medicine, American Urological Association and European Urological Association
• JAMA Patient Page: Peyronie’s Disease
• Peyronie’s Disease
• Peyronie’s disease: new paradigm for the treatment of a unique cause of erectile dysfunction

Substance Use Disorders

• NIH/National Institute on Drug Abuse – Patient Information
• Sublocade Prescribing Information
• Medication Assisted Treatment (MAT) Certification
• Substance Abuse & Mental Health Services Administration (SAMHSA) supported CME courses on prescribing opioids for chronic pain from AAAP, AOAAM, ASPMNDPT, ATTC and ASAM

Biosimilars

• Critical appraisal and future outlook on anti-inflammatory biosimilar use in chronic immune-mediated inflammatory diseases
• Biosimilars – What IBD Patients Should Know
• Biosimilar Patient and Prescriber Outreach Materials
• Biosimilar Development, Review, and Approval
• Biosimilars Basics infographic for Patients
• What is a Biosimilar?
• Prescribing Biosimilar Products
• Biosimilar Development Process

Cirrhosis

• How Do Patients With Cirrhosis and Their Caregivers Learn About and Manage Their Health? A Review and Qualitative Study
• Cirrhosis
• Hepatic Encephalopathy

Eosinophilic Esophagitis (EoE)

• Diagnosis and management of eosinophilic esophagitis
• AGA Institute and the Joint Task Force on Allergy-Immunology Practice Parameters Clinical Guidelines for the Management of Eosinophilic Esophagitis
• Disease Burden and Unmet Need in Eosinophilic Esophagitis
• Biologics in Eosinophilic Gastrointestinal Diseases
• Approaches and Challenges to Management of Pediatric and Adult Patients With Eosinophilic Esophagitis
• Treatment of Eosinophilic Esophagitis: Clinical Decision Support Tool

Hepatitis C Virus (HCV)

• AGA Hepatitis C Virus FAQs
• AGA GI Patient Center: Hepatitis C (HCV)
• Direct-Acting Antivirals: Side Effects Management Handouts
• CDC Hepatitis C Resource Center
• U.S. Department of Veterans Affairs: Hepatitis C Resources for Healthcare Professionals and Patients
• Direct-Acting Antivirals: Side Effects Management Handouts
• Hepatitis C Guidance 2019 Update: AASLD‐IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection

Hepatitis B Virus (HBV)

• CDC Patient Education Center: Hepatitis B Virus
• CDC Testing Asian Americans and Pacific Islanders for Hepatitis
• Q&A: HIV links to diminished control of HBV coinfection
• CDC Interpretation of Hepatitis B Serologic Test Results

Inflammatory Bowel Disease (IBD)

• AGA IBD Patient Resources
• Resources For Nurses & Advanced Practice Providers: Crohn’s and Colitis Foundation
• STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD
• Biologic Therapy for Inflammatory Bowel Disease: Real-World Comparative Effectiveness and Impact of Drug Sequencing in 13 222 Patients within the UK IBD BioResource
• Improving IBD outcomes in the era of many treatment options
• Comparative efficacy and safety of biologic therapies for moderate-to-severe Crohn’s disease: a systematic review and network meta-analysis
• Efficacy and safety of biologics and small molecule drugs for patients with moderate to severe ulcerative colitis: a systematic review and network meta-analysis

Crohn’s and Colitis Foundation Resources for Patients

• Crohn’s & Colitis Foundation. Free educational brochures
• Treatment Approaches in IBD: Shared Decision-Making
• Ostomy Tips and Tricks
• Living with Crohn’s Disease
• Living with Ulcerative Colitis
• CCF IBD Medication Guide
• UIcerative Colitis 101
• Crohn’s 101

Crohn’s and Colitis Foundation Resources for Clinicians:

• Inflammatory Bowel Diseases Clinical Primer and Care Pathway Tool Kit
• IBD Nurse & Advanced Practice Provider Best Practices Resource Library
• Appeal Letters

Lysosomal Acid Lipase Deficiency (LAL-D)

• Initial assessment and ongoing monitoring of lysosomal acid lipase deficiency in children and adults: Consensus recommendations from an international collaborative working group
• Lysosomal Acid Lipase Deficiency (LALD) – Patient Information

Non-Alcoholic Fatty Liver Disease (NAFLD)

• Review of Clinical Guidelines in the Diagnosis of Pediatric Nonalcoholic Fatty Liver Disease
• The diagnosis and management of nonalcoholic fatty liver disease: A patient‐friendly summary of the 2018 AASLD guidelines
• NAFLD: Differential Diagnosis – Summary
• NIH Genetic and Rare Diseases Information Center: Lysosomal acid lipase deficiency

Biosimilars

• Use of Biosimilar Medications in Oncology
• NCCN Guidelines for the Use of Biosimilars
• Biosimilar and Interchangeable Biologics: More Treatment Choices
• FDA’s Overview of the Regulatory Guidance for the Development and Approval of Biosimilar Products in the US
• Biosimilar Product Information

Bladder Cancer

• Bladder Cancer Treatment (PDQ®)–Health Professional Version
• Immunotherapy for Bladder Cancer – American Cancer Society
• Bladder Cancer – Nation Cancer Institute – For Patients
• Bladder Cancer – Nation Cancer Institute – For Providers

Breast Cancer

• Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low–Expressing Advanced Breast Cancer: Results From a Phase Ib Study
• Breast Cancer Treatment – Patient Information
• National Cancer Institute: Breast (Patient Version)
• National Cancer Institute: Breast (Health Professional Version)
• American Society of Clinical Oncology Breast Cancer Guidelines

Colorectal Cancer (CRC)

• Adjuvant Therapy for Stage II Colon Cancer: ASCO Guideline Update
• American Society of Clinical Oncology Gastrointestinal Cancer Guidelines
• US Preventive Services Task Force Colorectal Cancer: Screening—Final Recommendation Statement
• Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
• NCCN Guidelines for Colon Cancer
• NCCN Guidelines for Rectal Cancer
• Colorectal Cancer Alliance: What are NTRK fusions?
• Tropomyosin Receptor Kinase Inhibitors for the Treatment of TRK Fusion Cancer
• When should we order a next generation sequencing test in a patient with cancer?
• Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials
• Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials
• Colorectal Cancer Screening: What Are My Options?
• National Cancer Institute: Colorectal Cancer [patient version]
• National Cancer Institute: Colorectal Cancer [health professional version]
• National Cancer Institute: Drugs Approved for Colon and Rectal Cancer

General Hematology/Oncology

• Agency for Healthcare Research and Quality Technology Assessment Program. Role of Liquid Biopsy in Detection and Management of Cancer in the Medicare Population
• ASCO Supportive Care and Treatment Related Issues
• Somatic Genomic Testing in Patients With Metastatic or Advanced Cancer: ASCO Provisional Clinical Opinion
• Mismatch Repair and Microsatellite Instability Testing for Immune Checkpoint Inhibitor Therapy: ASCO Endorsement of College of American Pathologists Guideline
• Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set
• NCCN Clinical Practice Guidelines in Oncology
• NCCN Guidelines for Patients
• Increasing Cancer Screening Rates in Primary Care
• Non-invasive early detection of cancer four years before conventional diagnosis using a blood test
• Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA
• CDC Recommended Screening Tests for Cancer
• USPSTF Lung Cancer Screening Recommendations: 2021 Updates
• American Cancer Society Guidelines for the Early Detection of Cancer
• American Cancer Society guideline for diet and physical activity for cancer prevention

Hematologic Malignancies

• Novel Non-Immunologic Agents for Relapsed and Refractory Multiple Myeloma: A Review Article
• Proteasome Inhibitors for the Treatment of Multiple Myeloma
• Once- versus twice-weekly carfilzomib in relapsed and refractory multiple myeloma by select patient characteristics
• Carfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myeloma
• Carfilzomib, dexamethasone, and daratumumab for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study
• A real-world efficacy and safety analysis of combined carfilzomib, lenalidomide, and dexamethasone (KRd) in relapsed/refractory multiple myeloma
• Adjusted comparison between elotuzumab and carfilzomib in combination with lenalidomide and dexamethasone as salvage therapy for multiple myeloma patients
• Multiple Myeloma Disease Overview
• Multiple Myeloma – Treatment Overview for Patients and Caregivers
• Treatment for Multiple Myeloma – for Health Professionals
• National Cancer Institute: Leukemia (Patient Version)
• National Cancer Institute: Leukemia (Health Professional Version)
• National Cancer Institute: Plasma Cell Neoplasms (Including Multiple Myeloma (Patient Version)
• National Cancer Institute: Plasma Cell Neoplasms (Including Multiple Myeloma (Health Professional Version)
• NCCN CLL Guidelines for Patients
• Leukemia & Lymphoma Society Patient Information Booklets
• American Society of Clinical Oncology Hematologic Malignancies Guidelines
• Multiple Myeloma Research Foundation Patient Resources

Hematologic Malignancies and Disorders: Alpha Thalassemia

• Optimal strategies for carrier screening and prenatal diagnosis of α- and β-thalassemia
• Advances in the management of α -thalassemia major: reasons to be optimistic
• Safety and efficacy of mitapivat, an oral pyruvate kinase activator, in adults with non-transfusion dependent α-thalassaemia or β-thalassaemia: an open-label, multicentre, phase 2 study
• Alpha-Thalassemia
• What is Thalassemia?

Hematologic Malignancies and Disorders: B-cell Lymphomas

• Epcoritamab induces potent anti-tumor activity against malignant B-cells from patients with DLBCL, FL and MCL, irrespective of prior CD20 monoclonal antibody treatment
• Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell–Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial
• NCCN Guidelines for Patients: Mantle Cell Lymphoma
• NCCN Guidelines for Patients: Follicular Lymphoma
• NCCN Guidelines for Patients: DLBCL
• NCCN Clinical Practice Guidelines. B-Cell Lymphomas. Version 5.2022
• American Society of Clinical Oncology Hematologic Malignancies Guidelines
• Leukemia & Lymphoma Society Patient Information Booklets

Hematologic Malignancies and Disorders: Chronic Lymphocytic Leukemia (CLL)

• CLL Guide: Information for Patients and Caregivers
• NCCN Guidelines® Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 3.2022
• NCCN Guidelines: Chronic Lymphocytic Leukemia for Patients

Hematologic Malignancies and Disorders: Multiple Myeloma

• Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies
• Comparative Efficacy of Ciltacabtagene Autoleucel in CARTITUDE-1 vs Physician’s Choice of Therapy in the Long-Term Follow-Up of POLLUX, CASTOR, and EQUULEUS Clinical Trials for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
• Toxicity management strategies for next-generation novel therapeutics in multiple myeloma
• Patient experience before and after treatment with idecabtagene vicleucel (ide-cel, bb2121): qualitative analysis of patient interviews in the KarMMa trial
• Neurocognitive and hypokinetic movement disorder with features of parkinsonism after BCMA-targeting CAR-T cell therapy
• KarMMa-RW: comparison of idecabtagene vicleucel with real-world outcomes in relapsed and refractory multiple myeloma
• “Real-life” data of the efficacy and safety of belantamab mafodotin in relapsed multiple myeloma—the Mayo Clinic experience
• Ocular Toxicity of Commercially Available Belantamab Mafodotin in Patients with Advanced Multiple Myeloma
• The role of belantamab mafodotin for patients with relapsed and/or refractory multiple myeloma
• Risk Evaluation and Mitigation Strategy (REMS) Document BLENREP (belantamab mafodotin) REMS Program
• Belantamab Mafodotin for the Treatment of Multiple Myeloma: An Overview of the Clinical Efficacy and Safety
• Corneal Epithelial Findings in Patients with Multiple Myeloma Treated with Antibody-Drug Conjugate Belantamab Mafodotin in the Pivotal, Randomized, DREAMM-2 Study
• Management of belantamab mafodotin-associated corneal events in patients with relapsed or refractory multiple myeloma (RRMM)

Hematologic Malignancies and Disorders: Myelodysplastic Syndromes (MDS)

• NCCN Guidelines® Insights: Myelodysplastic Syndromes, Version 3.2022
• Myelodysplastic syndromes: 2021 update on diagnosis, risk stratification and management
• About Myelodysplastic Syndromes (MDS)
• Myelodysplastic Syndromes
• Treating MDS Toolkit
• The Diagnostic Spectrum of MDS, MDS/MPN, and MF Reference Card
• What is MDS? iPad App

Hemophilia

• World Federation of Hemophilia Guidelines for the Management of Hemophilia
• National Hemophilia Foundation Recommendations for Genotyping for Persons with Hemophilia
• Impact of novel hemophilia therapies around the world
• Centers for Disease Control and Prevention: Hemophilia Homepage
• National Hemophilia Foundation: Hemophilia A
• World Federation of Hemophilia: Guidelines for the Management of Hemophilia, 3rd Edition

Hepatocellular carcinoma

• National Cancer Institute: Liver and Bile Duct Cancers (Patient Version)
• National Cancer Institute: Liver and Bile Duct Cancers (Health Professional Version)

Kidney Cancer

• Management of Metastatic Clear Cell Renal Cell Carcinoma: ASCO Guideline
• Kidney Cancer – American Cancer Society
• Kidney Cancer – NIH – Patient Resources

Lung Cancer

• American Cancer Society Lung Cancer – Patient Information
• American Cancer Society Questions to Ask About Lung Cancer
• US Preventive Services Task Force Lung Cancer: Screening
• Dr Hatim Husain: NCCN Guidelines Adjust to Meet Lung Cancer Treatment Needs
• Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
• National Cancer Institute: Lung Cancer (Patient Version)
• National Cancer Institute: Lung Cancer (Health Professional Version)
• National Comprehensive Cancer Network (NCCN) Guidelines for Treatment of Cancer by Site
• IMpower, CASPIAN, and more: exploring the optimal first-line immunotherapy for extensive-stage small cell lung cancer

Melanoma

• Efficacy and safety of RP1 combined with nivolumab in patients with anti–PD-1–failed melanoma from the IGNYTE clinical trial
• Primary efficacy, safety, and survival data from the registration-intended cohort of patients with anti–PD-1–failed melanoma from the IGNYTE clinical trial with RP1 combined with nivolumab
• Open-label, phase II study of talimogene laherparepvec plus pembrolizumab for the treatment of advanced melanoma that progressed on prior anti–PD-1 therapy: MASTERKEY-115
• American Cancer Society: Immunotherapy for Melanoma Skin Cancer
• SITC Patient Resources: Melanoma and Other Skin Cancers
• Neoadjuvant Checkpoint Immunotherapy and Melanoma: The Time Is Now
• Adjuvant immunotherapy for melanoma patients: progress and opportunities
• Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial
• Neoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma
• Educational Review: Clinical Application of Immune Checkpoint Blockade for the Treatment of Melanoma
• Clinical updates in neoadjuvant immunotherapy for melanoma before surgery
• Adjuvant Therapy for High-Risk Melanoma: An In-Depth Examination of the State of the Field
• The introduction of LAG-3 checkpoint blockade in melanoma: immunotherapy landscape beyond PD-1 and CTLA-4 inhibition
• Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma
• Adjuvant Therapy for High-Risk Melanoma: An In-Depth Examination of the State of the Field
• NCI: Oncolytic Virus Enables the Immune System to Attack Tumors Subscribe
• Oncolytic virotherapy: basic principles, recent advances and future directions
• Breaking the barriers in cancer care: The next generation of herpes simplex virus-based oncolytic immunotherapies for cancer treatment
• Oncolytic viruses in melanoma
• Initial efficacy and safety of RP1 + nivolumab in patients with anti–PD-1–failed melanoma from the ongoing phase 1/2 IGNYTE study
• Melanoma Research Alliance: T-VEC
• Systemic Therapy for Melanoma: ASCO Guideline Rapid Recommendation Update
• What Screening Tests Are There?
• NCCN Guidelines for Patients: Melanoma
• NCCN Clinical Practice Guidelines in Oncology – Cutaneous Melanoma
• Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial
• 5-Year Outcomes with Cobimetinib plus Vemurafenib in BRAFV600 Mutation–Positive Advanced Melanoma: Extended Follow-up of the coBRIM Study
• Pathological response and survival with neoadjuvant therapy in melanoma
• The Status of Adjuvant and Neoadjuvant Melanoma Therapy, New Developments and Upcoming Challenges
• Targeted and immunotherapies in BRAF mutant melanoma: where we stand and what to expect
• Atezolizumab Prescribing Information
• Cobimetinib Prescribing Information
• Vemurafenib Prescribing Information
• Melanoma Treatment – for health professionals
• Melanoma Risk Assessment Tool
• Combination Therapy: Nivolumab + Ipilimumab
• Immunotherapy for Melanoma Skin Cancer
• Targeted Therapy for Melanoma
• The Skin Cancer Foundation: Skin Cancer 101 for Patients

Ovarian Cancer

• SGO Gynecologic Cancer Resources For Patients And Their Families
• ACOG Ovarian Cancer FAQs
• Assessment of Adult Women With Ovarian Masses and Treatment of Epithelial Ovarian Cancer: ASCO Resource-Stratified Guideline
• ASCO Guidelines: PARP Inhibitors in the Management of Ovarian Cancer—Rapid Update
• Germline and Somatic Tumor Testing in Epithelial Ovarian Cancer: ASCO Guideline
• Assessment of Adult Women With Ovarian Masses and Treatment of Epithelial Ovarian Cancer: ASCO Resource-Stratified Guideline
• National Cancer Institute: Ovarian, Fallopian Tube, and Primary Peritoneal Cancer (Patient Version)
• National Cancer Institute: Ovarian, Fallopian Tube, and Primary Peritoneal Cancer (Health Professional Version)

Uveal Melanoma

• Tebentafusp-tebn Prescribing Information
• National Comprehensive Cancer Network, NCCN Guidelines Melanoma: Uveal. Version 2.2021
• Intraocular (Uveal) Melanoma Treatment (PDQ®): Patient Version
• The Latest on Uveal Melanoma Research and Clinical Trials: Updates from the Cure Ocular Melanoma (CURE OM) Science Meeting (2019)
• Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma
• Immune Checkpoint Blockade for Metastatic Uveal Melanoma: Patterns of Response and Survival According to the Presence of Hepatic and Extrahepatic Metastasis
• Ipilimumab plus nivolumab for patients with metastatic uveal melanoma: a multicenter, retrospective study
• Quality of Life Concerns in Patients with Uveal Melanoma after Initial Diagnosis

Coronavirus (COVID-19)

• Ritonavir-Boosted Nirmatrelvir Prescribing Information
• Drug-Drug Interactions Between Ritonavir-Boosted Nirmatrelvir and Concomitant Medications
• The SARS-CoV-2 Monoclonal Antibody AZD3152 Potently Neutralizes Historical and Emerging Variants and is Being Developed for the Prevention and Treatment of COVID-19 in High-risk Individuals
• The Burden of COVID-19 in the Immunocompromised Patient: Implications for Vaccination and Needs for the Future
• Vaccines and therapeutics for immunocompromised patients with COVID-19
• Impact of COVID-19 on immunocompromised populations during the Omicron era: insights from the observational population-based INFORM study
• The Evolving Role of the Rheumatology Practitioner in the Care of Immunocompromised Patients in the COVID-19 Era
• Long COVID: major findings, mechanisms and recommendations
• Pre-exposure prophylaxis with tixagevimab and cilgavimab (Evusheld) for COVID-19 among 1112 severely immunocompromised patients
• The COVID-19 Pandemic Rages on for People Who Are Immunocompromised
• CDC: COVID-19 Vaccines for People Who Are Moderately or Severely Immunocompromised
• IDSA and CDC COVID-19 Real-Time Learning Network: Immunocompromised Populations
• Intramuscular AZD7442 (Tixagevimab–Cilgavimab) for Prevention of Covid-19
• COVID-19 Drug Interactions
• Dexamethasone in Hospitalized Patients with Covid-19
• IDSA Guidelines on the Treatment and Management of Patients with COVID-19
• Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalized adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation
• Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia
• Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19
• NIH COVID-19 Treatment Guidelines
• FDA COVID-19 Emergency Use Authorizations: Drug and Biological Therapeutic Products
• Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19 (ACTT-2)
• Efficacy and safety of baricitinib for the treatment of hospitalized adults with COVID-19 (COV-BARRIER)
• Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis
• Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY)
• CDC Coronavirus Disease 2019 (COVID-19) Resources
• WHO Resources: COVID-19 Pandemic
• Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients
• Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19
• JAMA Patient Page: Oral antiviral medications for COVID-19
• Molnupiravir EUA
• Nirmatrelvir EUA

Gram-negative Bacterial Infections

• Gram-negative Bacteria Infections in Healthcare Settings
• IDSA Guidance on the Treatment of Antimicrobial-Resistant Gram-Negative Infections: Version 1.0
• Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial
• New Perspectives on Antimicrobial Agents: Cefiderocol

Cytomegalovirus (CMV)

• Letermovir for Secondary Prophylaxis of CMV Infection
• Letermovir and its role in the prevention of cytomegalovirus infection in seropositive patients receiving an allogeneic hematopoietic cell transplant
• Consensus Guidelines on the Management of Cytomegalovirus in Solid-organ Transplantation
• Cytomegalovirus (CMV) Infection
• About CMV for Patients
• Clinical manifestations, diagnosis, and management of CMV disease in kidney transplant recipients

Herpes Zoster

• What You Can Expect After Getting Shingrix Vaccine Fact Sheet

HIV

• Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV
• INSTI Drug Interactions
• HIV and Drug-resistance Testing
• Evidence-based Interventions to Improve HIV Medication Adherence
• Optimizing Antiretroviral Therapy in the Setting of Virologic Suppression
• Adherence to the Continuum of Care
• Drug-Drug Interactions
• Drug Database: Cabotegravir
• Women with HIV
• Adverse Effects of Antiretroviral Therapy
• Considerations for Antiretroviral Therapy in the Older Patient
• Stanford University HIV Drug Resistance Database
• Understanding HIV Laboratory Tests – for Patients
• NNRTI Drug Interactions
• NRTI Drug Interactions
• PI Drug Interactions
• Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents- Tables
• What to Start: Selecting a First HIV Regimen

PrEP

• Patient/Clinician Handout: PrEP 2-1-1
• HIV PrEP With FTC/TDF Among Cisgender Women
• Equity of Prep Uptake by Race, Ethnicity, Sex, and Region in the US in the First Decade of Prep
• Characteristics Associated with PrEP Discussion and Use Among Transgender Women Without HIV Infection – National HIV Behavioral Surveillance
• Postexposure Doxycycline to Prevent Bacterial Sexually Transmitted Infections
• Safety Review of TDF/FTC PrEP for Pregnant Women at Risk of HIV Infection
• PrEP Resources in all 50 States
• National Clinician Consultation Center for PrEP
• Preexposure Prophylaxis for the Prevention of HIV Infection of the United States – 2021 Update
• Quick Guide: 2021 PrEP Update
• Pre-Exposure Prophylaxis (PrEP)
• HIV Prevention Materials for Your Practice
• Let’s Stop HIV Together: HIV Prevention
• Drug information on cabotegravir
• Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women (HPTN 083)
• Long acting injectable cabotegravir is safe and effective in preventing HIV infection in cisgender women: results from HPTN 084

Influenza

• Influenza Antiviral Drug Resistance
• A real-world study evaluating the relative vaccine effectiveness of a cell-based quadrivalent influenza vaccine compared to egg-based quadrivalent influenza vaccine in the US during the 2017–18 influenza season – ScienceDirect
• Influenza vaccines: the potential benefits of cell-culture isolation and manufacturing
• Baloxavir Marboxil for Prophylaxis against Influenza in Household Contacts
• Seasonal Influenza Vaccine Effectiveness Studies
• Influenza Antiviral Medications: Summary for Clinicians
• FDA-cleared Nucleic Acid Detection Based Tests for Influenza Viruses
• Information for Clinicians on Influenza Virus Testing
• What You Should Know About Influenza (Flu) Antiviral Drugs
• People at High Risk For Flu Complications
• Baloxavir Marboxil Single-dose Treatment in Influenza-infected Children
• Early Treatment With Baloxavir Marboxil in High-Risk Adolescent and Adult Outpatients With Uncomplicated Influenza (CAPSTONE-2): A Randomised, Placebo-controlled, Phase 3 Trial
• Similarities and Differences between Flu and COVID-19

Invasive Fungal Infections

• CDC Fungal Diseases – Patient Information
• Information for Healthcare Professionals about Invasive Candidiasis
• Information for Healthcare Professionals about Mucormycosis
• Information for Healthcare Professionals about Aspergillosis

Molecular Diagnostics

• Panels and Syndromic Testing in Clinical Microbiology
• Advances in rapid diagnostics for bloodstream infections
• Diagnostic test accuracy of the BioFire® FilmArray® meningitis/encephalitis panel: a systematic review and meta-analysis
• Relationship of Multiplex Molecular Pneumonia Panel Results With Hospital Outcomes and Clinical Variables
• Enhanced Detection of Community-Acquired Pneumonia Pathogens With the BioFire® Pneumonia FilmArray® Panel

Pediatrics

• Recommendations for Prevention and Control of Influenza in Children, 2022–2023
• Cryptosporidiosis
• Giardiasis
• Swimming Pool Hygiene
• Facts About Crypto and Swimming Pools – Patient Handout
• Human Papillomavirus (HPV): The Need to Immunize – Patient Handout

Pneumococcal Disease

• Advisory Committee on Immunization Practices (ACIP): Pneumococcal Vaccine Recommendations
• Updated ACIP Recommendations and Evidence Review: Use of 15-Valent Pneumococcal Conjugate Vaccine Among U.S. Children
• Updated ACIP Recommendations and Evidence Review: Use of PCV15 and PCV20 Among US Adults
• Immunize.org Ask the Experts: Pneumococcal Vaccines for Children and Adults
• Pneumococcal Vaccination
• AAFP: Simplifying Pneumococcal Immunizations for Adults
• Burden of pneumococcal disease due to serotypes covered by the 13-valent and new higher-valent pneumococcal conjugate vaccines in the United States
• Pneumococcal Conjugate Vaccine Breakthrough Infections: 2001-2016
• PneumoRecs VaxAdvisor Mobile App
• Marked Reduction of Socioeconomic and Racial Disparities in Invasive Pneumococcal Disease Associated With Conjugate Pneumococcal Vaccines
• PCV15 Prescribing Information
• PCV20 Prescribing Information

Respiratory Syncytial Virus (RSV)

• RSV surges early in 2022, but appears to make early retreat
• Updated Guidance: Use of Palivizumab Prophylaxis to Prevent Hospitalization From Severe Respiratory Syncytial Virus Infection During the 2022-2023 RSV Season
• Multiple RSV vaccines in late-stage development show promise in older adults
• CYPRESS Phase 2b Data on the Efficacy and Immunogenicity of an Ad26.RSV.preF-based RSV Vaccine
• Incidence of Respiratory Syncytial Virus Infection Among Hospitalized Adults, 2017-2020
• A Phase 1/2 Study of a Respiratory Syncytial Virus Prefusion F Vaccine With and Without Adjuvant in Healthy Older Adults
• Respiratory Syncytial Virus (RSV)
• CDC Factsheet. RSV in Older Adults and Adults with Chronic Medical Conditions
• Prevention of Respiratory Syncytial Virus Infection in Healthy Adults by a Single Immunization of Ad26.RSV.preF in a Human Challenge Study
• Respiratory Syncytial Virus Infection

• Provider Resource: Interprofessional Collaborative Practice
  
• Provider Resource: Six-A Model of Counseling

Chronic Kidney Disease (CKD)

• Profile of Daprodustat in the Treatment of Renal Anemia Due to Chronic Kidney Disease
• Daprodustat for the Treatment of Anemia in Patients Not Undergoing Dialysis
• Daprodustat for the Treatment of Anemia in Patients Undergoing Dialysis
• Vadadustat in Patients with Anemia and Non–Dialysis-Dependent CKD
• Safety and Efficacy of Vadadustat for Anemia in Patients Undergoing Dialysis
• Roxadustat for anemia in patients with end-stage renal disease incident to dialysis
• Roxadustat for Treating Anemia in Patients with CKD Not on Dialysis: Results from a Randomized Phase 3 Study
• Roxadustat for CKD-related Anemia in Non-dialysis Patients
• Anemia in Chronic Kidney Disease
• FDA Approves First Oral Treatment for Anemia Caused by Chronic Kidney Disease for Adults on Dialysis

Alzheimer’s Disease

• Revised criteria for diagnosis and staging of Alzheimer’s disease: Alzheimer’s Association Workgroup
• Alzheimer’s Disease Facts and Figures 2024
• Focusing on earlier diagnosis of Alzheimer’s disease
• For Patients: Treatments for Alzheimer’s
• Alzheimer’s Disease: Key Insights from Two Decades of Clinical Trial Failures
• Alzheimer’s disease drug development pipeline
• Treatment with GLP-1 RAs and incidence of dementia
• Donanemab in Early Symptomatic Alzheimer Disease
• Alzforum: news and information dedicated to Alzheimer’s disease

Amyotrophic Lateral Sclerosis

• NIH Amyotrophic Lateral Sclerosis Fact Sheet
• Edaravone Prescribing Information
• ALS Association

Migraine

• Frequently Asked Questions About Migraine Symptoms
• Atogepant for the Preventive Treatment of Migraine

Multiple Sclerosis (MS)

• Clinician Pocket Guide: What to Screen For and What to Follow When Using Disease-Modifying Therapies (DMTs)
• MS, COVID-19 and vaccines – updated global advice
• Multiple Sclerosis Therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper)
• Aging and efficacy of disease-modifyingtherapies in multiple sclerosis: a meta-analysis of clinical trials
• Monitoring of safety and effectiveness of cladribine in multiple sclerosis patients over 50 years
• BEACON: BEtaferon prospective study on Adherence, COping and Nurse support): Clinical characteristics of middle-aged and older patients with MS treated with interferon beta-1b
• Guidelines of the Consortium of MS Centers MRI Protocol for the Diagnosis and Follow-up of MS
• Adherence — Patient Information
• Resources for You and Your Practice
• Mobile Applications for People with Multiple Sclerosis (MS)
• Family Planning and Pregnancy With Multiple Sclerosis
• Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis
• Disease-modifying Therapies for MS

Parkinson’s Disease

• The On-Off Phenomenon
• On-Off Phenomenon: When Levodopa Stops Working as Well

Stroke

• Impact of Echocardiographic Parameters on Recurrent Stroke in the Randomized REDUCE PFO Cryptogenic Stroke Trial
• Heterogeneity of Treatment Effects in an Analysis of Pooled Individual Patient Data From Randomized Trials of Device Closure of Patent Foramen Ovale After Stroke
• Etiologic Workup in Cases of Cryptogenic Stroke: A Systematic Review of International Clinical Practice Guidelines
• Inclusion and Exclusion Criteria for Intravenous Alteplase in Acute Ischemic Stroke
• Signs and Symptoms of a Stroke
• Recognize Warning Signs of a Stroke (Act FAST)
• Proposal for Updated Nomenclature and Classification of Potential Causative Mechanism in Patent Foramen Ovale-Associated Stroke
• American Academy of Neurology practice advisory update: Patent foramen ovale and secondary stroke prevention
• REDUCE trial: Five-Year Outcomes of PFO Closure or Antiplatelet Therapy for Cryptogenic Stroke

• Clinical Recommendations to Manage Gastrointestinal Adverse Events in Patients Treated with Glp-1 Receptor Agonists: A Multidisciplinary Expert Consensus
• AGA Clinical Practice Guideline on Pharmacological Interventions for Adults With Obesity
• Clinical Practice Guideline for the Evaluation and Treatment of Children and Adolescents With Obesity
• Patient Resource: Your Obesity Care Team
• Internet Tracking Tools for the Bariatric Patient
• CDC: Healthy Weight, Nutrition, and Physical Activity—Planning Meals
• Who’s Who on the Obesity Care Team – Patient Education
• 2023 Consensus Statement on Obesity
• Curated Resources for the Management of Obesity in the Primary Care Setting
• Guide for the Management of Obesity in the Primary Care Setting
• Prescription Medications to Treat Overweight and Obesity
• Bariatric Surgery: Patient Materials
• STOP Obesity Alliance – WHY WEIGHT? A Guide to Discussing Obesity & Health with Your Patients
• American Board of Obesity Medicine (ABOM)
• How To Use Fruits and Vegetables – Patient Handout
• Rethink Your Drink – Patient Materials
• Childhood Obesity Facts

Age-Related Macular Degeneration (AMD)

• Age-Related Macular Degeneration (AMD) for Patients
• Impact of Anti-VEGF on Vision Outcomes in nAMD: 6-Year Analysis of the AAO IRIS® Registry
• TENAYA/LUCERNE: Two-Year Results from the Phase 3 nAMD Trials of Faricimab with T&E Dosing
• Aflibercept 8 mg in nAMD (PULSAR): 48-week results from a randomised, double-masked, non-inferiority, phase 3 trial
• The real-world efficacy and safety of faricimab in nAMD: TRUCKEE study – 6 month results
• Review of real-world evidence of faricimab in nAMD and DME
• PULSAR: Intravitreal Aflibercept 8 mg in nAMD: 48-Week Results, Phase 3 Trial
• RGX-314: Gene Therapy for nAMD by Subretinal Delivery: Phase 1/2a Dose Escalation Study
• OPT-302: VEGF-C/D Inhibitor for nAMD: Phase 2b Trial
• OPTIC: Ixoberogene soroparvovec for nAMD: Phase 1 Study
• Gene Therapy for Retinal Degenerative Diseases: Progress, Challenges, and Future Directions
• Effect of High-Dose Intravitreal Aflibercept, 8 mg, in Patients With Neovascular Age-Related Macular Degeneration: The Phase 2 CANDELA Randomized Clinical Trial
• Port delivery system with ranibizumab (Susvimo) recall: What does it mean to the retina specialists
• Comprehensive Preclinical Assessment of ADVM-022, an Intravitreal Anti-VEGF Gene Therapy for the Treatment of Neovascular AMD and Diabetic Macular Edema
• Suprachoroidal Delivery of RGX-314 Well-Tolerated in Wet AMD
• FDA approves faricimab for treatment of wet AMD, DME
• TENAYA and LUCERNE: Rationale and Design for the Phase 3 Clinical Trials of Faricimab for Neovascular Age-Related Macular Degeneration
• Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials
• YOSEMITE and RHINE Phase 3 Randomized Clinical Trials of Faricimab for Diabetic Macular Edema: Study Design and Rationale
• Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials
• Archway Randomized Phase 3 Trial of the Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration
• Port delivery system: a novel drug delivery platform to treat retinal diseases
• Review of gene therapies for age-related macular degeneration.
• Efficacy and safety of intravitreal aflibercept using a treat-and-extend regimen for neovascular age-related macular degeneration: The ARIES Study: A Randomized Clinical Trial
• Efficacy of a Treat-and-Extend Regimen With Ranibizumab in Patients With Neovascular Age-Related Macular Disease
• Faricimab shows efficacy, safety and durability in treatment of wet AMD
• Management and Outcomes for Neovascular Age-Related Macular Degeneration: Analysis of United States Electronic Health Records
• Impact of intravitreal aflibercept dosing regimens in treatment-naïve patients with neovascular age-related macular degeneration: 2-year results of RAINBOW
• Real-World Effectiveness and Real-World Cost-Effectiveness of Intravitreal Aflibercept and Intravitreal Ranibizumab in Neovascular Age-Related Macular Degeneration: Systematic Review and Meta-Analysis of Real-World Studies
• Efficacy and Safety of Intravitreal Aflibercept Treat-and-Extend Regimens in Exudative Age-Related Macular Degeneration: 52- and 96-Week Findings from ALTAIR
• Evaluation of Intravitreal Aflibercept for the Treatment of Severe Nonproliferative Diabetic Retinopathy: Results From the PANORAMA Randomized Clinical Trial
• Effect of Intravitreous Anti–Vascular Endothelial Growth Factor vs Sham Treatment for Prevention of Vision-Threatening Complications of Diabetic Retinopathy: The Protocol W Randomized Clinical Trial
• End of Study Results for the Ladder Phase 2 Trial of the Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration
• Gene therapy for neovascular age-related macular degeneration: rationale, clinical trials and future directions
• Efficacy and Safety of Abicipar in Neovascular Age-Related Macular Degeneration
• Port Delivery System With Ranibizumab Shows Positive Phase III Results in Neovascular Age-Related Macular Degeneration
• What AREDS means for you?
• Mayo Clinic: Dry Macular Degeneration
• Understanding Your AMD – Patient Handout
• Protecting Eye Health and Possibly Reducing Risk for Developing Macular Degeneration – Patient Handout
• Results from the Phase 3 HAWK and HARRIER Studies
• Age-Related Macular Degeneration (AMD) Data and Statistics – Patient Education
• Efficacy of Every Four Monthly and Quarterly Dosing of Faricimab vs Ranibizumab in Neovascular Age-Related Macular Degeneration

Cataract and/or Refractive Surgery

• AAO Refractive Surgery Preferred Practice Patterns 2024
• Saving of Time Using a Software-Based versus a Manual Workflow for Toric Intraocular Lens Calculation and Implantation
• Application of artificial intelligence in cataract management: current and future directions
• Latest Development in Extended Depth-of-Focus Intraocular Lenses: An Update
• AAO Cataract in the Adult Eye Preferred Practice Pattern 2021
• Cataract and Refractive Lens Exchange Questionnaire
• Post-Refractive IOL Calculator
• American Society of Cataract and Refractive Surgery
• Physician Quality Reporting System Measures Associated with Cataract Surgery
• Toric IOL Calculator
• Preparing for Cataract Surgery – Postoperative Concerns – Patient Handout

Conjunctivitis

• Conjunctivitis (Pink Eye) Treatment
• Conjunctivitis: What is Pink Eye? – Patient Information
• Help Protect Yourself From Getting & Spreading Pink Eye (Conjunctivitis) – Patient Handout

Diabetic Macular Edema (DME)

• Diabetic Retinopathy Preferred Practice Pattern
• Long-term Treatment Patterns for DME: 6-Year Follow-Up in the IRIS® Registry
• YOSEMITE/RHINE: Results from the Phase 3 DME Trials of Faricimab with T&E Dosing
• Aflibercept 8 mg in DME (PHOTON): 48-week results from a randomised, double-masked, non-inferiority, phase 2/3 trial
• PHOTON: Intravitreal Aflibercept 8 mg in DME: 48-Week Results, Phase 2/3 Trial
• KESTREL and KITE Phase 3 studies: 100-week results with brolucizumab in patients with diabetic macular edema
• Two-year interim safety results of the 0.2 µg/day fluocinolone acetonide intravitreal implant for the treatment of diabetic macular oedema: the observational PALADIN study
• A Collaborative Retrospective Study on the Efficacy and Safety of Intravitreal Dexamethasone Implant in Patients with Diabetic Macular Edema: The European DME Registry Study
• Aqueous Cytokine Expression and Higher Order OCT Biomarkers: Assessment of the Anatomic-Biologic Bridge in the IMAGINE DME Study
• The Mechanism of the Bispecific Antibody Faricimab
• Differential response to intravitreal dexamethasone implant in naïve and previously treated diabetic macular edema eyes
• Understanding How Diabetes Can Affect Your Vision and Cause Diabetic Macular Edema – Patient Handout
• Facts About Macular Edema
• 5 Year Outcomes After Aflibercept, Bevacizumab, or Ranibizumab for DME: Protocol T Extension Study
• Assessment of the DRCR Retina Network Approach to Management With Initial Observation for Eyes With Center-Involved Diabetic Macular Edema and Good Visual Acuity: A Secondary Analysis of a Randomized Clinical Trial
• Treatment Patterns for Diabetic Macular Edema: An Intelligent Research in Sight (IRIS®) Registry Analysis
• Evaluation of Patients Receiving Intravitreal Antivascular Endothelial Growth Factor for Diabetic Macular Edema in Clinical Practice in the United States

Diabetic Retinopathy

• Retina Summary Benchmarks, 2023 (for Patients)
• Understanding Diabetic Retinopathy – Patient Handout
• Diabetic Retinopathy Clinical Research Network Publications
• Diabetic Retinopathy: Causes, Symptoms, Treatment
• PANORAMA: Evaluation of Intravitreal Aflibercept for the Treatment of Severe Nonproliferative Diabetic Retinopathy
• Protocol W: Effect of Intravitreous Anti–Vascular Endothelial Growth Factor vs Sham Treatment for Prevention of Vision-Threatening Complications of Diabetic Retinopathy
• Risk of Blindness Among Patients With Diabetes and Newly Diagnosed Diabetic Retinopathy

Geographic Atrophy

• Geographic atrophy: Mechanism of disease, pathophysiology, and role of the complement system
• Considerations for the Identification and Management of Geographic Atrophy: Recommendations from an Expert Panel
• Consensus Definition for Atrophy Associated with Age-Related Macular Degeneration on OCT Classification of Atrophy Report 3
• OAKS/DERBY: Pegcetacoplan for GA Secondary to AMD: Phase 3 Trials
• GATHER2: Avacincaptad pegol for GA: Phase 3 Trial
• Understanding Geographic Atrophy in Advanced Non-Exudative Age-Related Macular Degeneration: a Teaching Case Report
• Seeing Beyond Anatomy: Quality of Life with Geographic Atrophy
• Seeing Beyond Anatomy: Quality of Life with Geographic Atrophy
• Clinically relevant deep learning for detection and quantification of geographic atrophy from optical coherence tomography: a model development and external validation study
• Complement C3 Inhibitor Pegcetacoplan for Geographic Atrophy Secondary to Age-Related Macular Degeneration: A Randomized Phase 2 Trial
• C5 Inhibitor Avacincaptad Pegol for Geographic Atrophy Due to Age-Related Macular Degeneration
• Prevalence and phenotype associations of complement factor I mutations in geographic atrophy
• Natural History of Geographic Atrophy Secondary to Age-Related Macular Degeneration
• Pegcetacoplan treatment for geographic atrophy due to age-related macular degeneration: a plain language summary of the FILLY study
• Predicting Topographic Disease Progression and Treatment Response of Pegcetacoplan in Geographic Atrophy Quantified by Deep Learning
• Color Vision and Microperimetry Changes in Nonexudative Age-Related Macular Degeneration After Risuteganib Treatment: Exploratory Endpoints in a Multicenter Phase 2a Double-Masked, Randomized, Sham-Controlled, Crossover Clinical Trial

General

• ICD-10-CM for Ophthalmology
• EyeNet Magazine
• National Institutes of Health Guidelines on Human Subjects Research
• AAO Preferred Practice Patterns
• American Academy of Ophthalmology. Teleophthalmology: how to get started.
• Centers for Medicare and Medicaid Services. Medicare telemedicine health care provider fact sheet.
• Vicchrilli S. Savvy coder: telemedicine during the public health emergency.
• AAO.org: Home Eye Test for Adults

Glaucoma

• CDC Vision Health Initiative: Facts About Glaucoma
• Bimatoprost Implant Biodegradation in the Phase 3, Randomized, 20-Month ARTEMIS Studies
• The effectiveness and safety profile of netarsudil 0.02% in glaucoma treatment: real-world 6-month outcomes
• A multicenter, open-label study of netarsudil for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension in a real-world setting
• Real-World Clinical Impact of Netarsudil 0.02% at an Urban Safety-Net Hospital
• National Eye Institute: Glaucoma
• Advances in medical therapy for glaucoma
• New glaucoma medications: latanoprostene bunod, netarsudil, and fixed combination netarsudil-latanoprost
• Fixed-Dose Combination of Netarsudil and Latanoprost in Ocular Hypertension and Open-Angle Glaucoma: Pooled Efficacy/Safety Analysis of Phase 3 MERCURY-1 and -2
• Short-term efficacy of latanoprostene bunod for the treatment of open-angle glaucoma and ocular hypertension: a systematic literature review and a network meta-analysis
• 2 Year Experience with Latanoprostene Bunod in Clinical Practice
• Sustained-release drug delivery systems for the treatment of glaucoma
• Investigational Rho Kinase Inhibitors for the Treatment of Glaucoma
• Causes of blindness and vision impairment in 2020 and trends over 30 years, and prevalence of avoidable blindness in relation to VISION 2020: the Right to Sight: an analysis for the Global Burden of Disease Study
• Prospective Study of NCX 470 for IOP Lowering: Phase 2 Clinical Results
• Phase 3, Randomized, 20-Month Study of Bimatoprost Implant in Open-Angle Glaucoma and Ocular Hypertension (ARTEMIS 1)
• Bimatoprost Implant. Prescribing Information
• Microinvasive Glaucoma Surgery (MIGS)
• Xen Gel Stent: Directions for Use
• American Glaucoma Society
• Facts About Glaucoma

Inherited Retinal Diseases

• Advancing Clinical Trials for Inherited Retinal Diseases: Recommendations from the Second Monaciano Symposium
• Genetic testing and diagnosis of inherited retinal diseases
• AAO Guidelines on Clinical Assessment of Patients with Inherited Retinal Degenerations – 2022
• Genetic testing for inherited retinal degenerations: Triumphs and tribulations
• Patient Information – Inherited Retinal Diseases
• Foundation Fighting Blindness

Macular Disorders

• Revised Definitions from the International Classification of Diseases of the Vitreomacular Interface
• Understanding Vitreomacular Traction Syndrome – Patient Handout
• Managing Challenging Macular Holes

Macular Telangiectasia

• Macular Telangiectasia Type 2: A Comprehensive Review

Neurotrophic Keratitis

• Amniotic membrane transplantation for managing dry eye and neurotrophic keratitis
• Cenegermin Prescribing Information
• Phase IV Multicenter, Prospective, Open-Label Clinical Trial of Cenegermin (rhNGF) for Stage 1 Neurotrophic Keratopathy (DEFENDO)
• Neurotrophic keratopathy: An updated understanding
• Long-term clinical efficacy of topical treatment with recombinant human nerve growth factor in neurotrophic keratopathy: a novel cure for a rare degenerative corneal disease?
• Topical human recombinant nerve growth factor for stage 1 Neurotrophic Keratitis: Retrospective case series of cenegermin treatment.
• Topical Recombinant Human Nerve Growth Factor (Cenegermin) for Neurotrophic Keratopathy
• Amniotic membrane transplantation for managing dry eye and neurotrophic keratitis
• Neurotrophic keratopathy: current challenges and future prospects
• Expert consensus on the identification, diagnosis, and treatment of neurotrophic keratopathy
• Cenegermin: A Review in Neurotrophic Keratitis

Neuromyelitis Optica Spectrum Disorder (NMOSD)

• Update on the diagnosis and treatment of neuromyelits optica spectrum disorders (NMOSD) – revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part I: Diagnosis and differential diagnosis
• International Delphi Consensus on the Management of AQP4-IgG+ NMOSD. Recommendations for Eculizumab, Inebilizumab, and Satralizumab
• Contemporary management challenges in seropositive NMOSD
• Guthy Jackson Foundation
• Impact of Neuromyelitis Optica Spectrum Disorder on Quality of Life from the Patients’ Perspective: An Observational Cross-Sectional Study
• Pain, Depression, and Quality of Life in Neuromyelitis Optica Spectrum Disorder
• AQP4-IgG-seronegative patient outcomes in the N-MOmentum trial of inebilizumab in NMOSD
• Long-term efficacy and safety of inebilizumab in NMOSD: Analysis of AQP4-IgG seropositive participants taking inebilizumab for ⩾4 years in the N-MOmentum trial
• Disability Outcomes in the N-MOmentum Trial of Inebilizumab in Neuromyelitis Optica Spectrum Disorder
• Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder (SAkuraStar)
• Neuromyelitis Optica Spectrum Disorder
• The Sumaira Foundation for NMO

Ocular Surface and Lid Margin Disease

• Care of the Patient with Ocular Surface Disorders
• NOV03 for Dry Eye Disease Associated with Meibomian Gland Dysfunction
• TFOS Lifestyle: Impact of nutrition on the ocular surface
• Dry eye syndrome: comprehensive etiologies and recent clinical trials
• Dry eye disease: identification and therapeutic strategies for primary care clinicians and clinical specialists
• Omega-3 fatty acids in the management of dry eye disease—An updated systematic review and meta-analysis
• A Randomized Clinical Study (SEECASE) to Assess Efficacy, Safety, and Tolerability of NOV03 for Treatment of Dry Eye Disease
• Efficacy of NOV03 (Perfluorohexyloctane) on Signs and Symptoms of Dry Eye Disease associated with Meibomian Gland Dysfunction: The Mojave study
• Optimization of the Ocular Surface Through Treatment of Ocular Surface Disease Before Ophthalmic Surgery: A Narrative Review
• Racial and Ethnic Disparities in Dry Eye Diagnosis and Care
• Efficacy of the Systane iLux Thermal Pulsation System for the Treatment of Meibomian Gland Dysfunction After 1 Week and 1 Month: A Prospective Study
• Comparison of Two Thermal Pulsation Systems in the Treatment of Meibomian Gland Dysfunction: A Randomized, Multicenter Study
• Practical Guidance for the Use of Loteprednol Etabonate Ophthalmic Suspension 0.25% in the Management of Dry Eye Disease
• Selective Pharmacologic Therapies for Dry Eye Disease Treatment: Efficacy, Tolerability, and Safety Data Review from Preclinical Studies and Pivotal Trials
• AAO EyeWiki: Meibomian Gland Dysfunction (MGD)
• NIH Dry Eye Patient Information
• Lotilaner Ophthalmic Solution, 0.25%, for the Treatment of Demodex Blepharitis: Results of a Prospective, Randomized, Vehicle-Controlled, Double-Masked, Pivotal Trial (Saturn-1)
• Demodex and Eye Disease
• Efficacy and Safety of OC-01 (Varenicline Solution) Nasal Spray on Signs and Symptoms of Dry Eye Disease: The ONSET-2 Phase 3 Randomized Trial
• A phase II randomized trial to evaluate the long-term (12-week) efficacy and safety of OC-01 (varenicline solution) nasal spray for dry eye disease: The MYSTIC study
• Emerging therapies for dry eye disease
• AAO: Improved Dry Eye Drugs for 2022 and Beyond
• The role of KPI-121 0.25% in the treatment of dry eye disease: penetrating the mucus barrier to treat periodic flares
• New strategies for the management of ocular surface disease in glaucoma patients
• Phase 3 Efficacy (Worse-Eye Analysis) and Long-Term Safety Evaluation of OTX-101 in Patients with Keratoconjunctivitis Sicca
• Efficacy and Safety of OTX-101, a Novel Nanomicellar Formulation of Cyclosporine A, for the Treatment of Keratoconjunctivitis Sicca: Pooled Analysis of a Phase 2b/3 and Phase 3 Study
• Safety of KPI-121 Ophthalmic Suspension 0.25% in Patients With Dry Eye Disease: A Pooled Analysis of 4 Multicenter, Randomized, Vehicle-Controlled Studies
• Comparison of the iLUX and the LipiFlow for the Treatment of Meibomian Gland Dysfunction and Symptoms: A Randomized Clinical Trial
• Dupilumab-associated ocular surface disease: presentation, management and long-term sequelae
• Diseases of Ocular Surface
• Dry Eye: Patient Information
• American Academy of Ophthalmology Preferred Practice Patterns: Dry Eye Syndrome
• American Academy of Ophthalmology Preferred Practice Patterns: Blepharitis
• Sjögren’s Syndrome Foundation

Presbyopia

• Living with presbyopia: experiences from a virtual roundtable dialogue among impacted individuals and healthcare professionals
• In Vitro and In-Eye Comparison of Commercial Pilocarpine Ophthalmic Solution and an Optimized, Reformulated Pilocarpine for Presbyopia Treatment
• Review of Presbyopia Treatment with Corneal Inlays and New Developments
• Safety and Efficacy of AGN-190584 in Individuals With Presbyopia The GEMINI 1 Phase 3 Randomized Clinical Trial
• 1.25% Pilocarpine for Presbyopia
• Potential new presbyopia treatments in development
• What Is Presbyopia? (Patient Material)
• A Review of Pharmacological Presbyopia Treatment
• Treatments for presbyopia coming soon

Retinal Vascular Diseases (RVO)

• Relationship Between Nerve Fiber Layer Hemorrhages and Outcomes in Central Retinal Vein Occlusion
• Efficacy and Safety of Intravitreal Aflibercept Treat-and-Extend for Macular Edema in Central Retinal Vein Occlusion: the CENTERA Study
• Visual acuity outcomes and anti-VEGF therapy intensity in macular oedema due to retinal vein occlusion: a real-world analysis of 15 613 patient eyes
• Real world evidence on 5661 patients treated for macular oedema secondary to branch retinal vein occlusion with intravitreal anti-vascular endothelial growth factor, intravitreal dexamethasone or macular laser
• Twelve-month outcomes of ranibizumab versus aflibercept for macular oedema in branch retinal vein occlusion: data from the FRB! registry
• Branch Retinal Vein Occlusion Information for Patients
• Central Retinal Vein Occlusion Information for Patients
• Understanding Your Retinal Vein Occlusion (RVO) – Patient Handout

Thyroid Eye Disease (TED)

• Efficacy and Safety of Teprotumumab in Patients With Thyroid Eye Disease of Long Duration and Low Disease Activity
• Teprotumumab-Related Hyperglycemia
• Thyroid Eye Disease: Navigating Diagnosis and Treatment
• Patient Brochures
• Navigating the New Treatment Landscape
• Graves’ Eye Disease: Patient Information from the American Thyroid Association
• Teprotumumab Efficacy, Safety, and Durability in Longer-Duration Thyroid Eye Disease and Re-treatment OPTIC-X Study
• Future Projections in Thyroid Eye Disease
• Patient Material: Examining the Optics of TED
• Teprotumumab and the Evolving Therapeutic Landscape in Thyroid Eye Disease
• Therapeutic IGF-I receptor inhibition alters fibrocyteimmune phenotype in thyroid-associated ophthalmopathy
• Hearing Dysfunction After Treatment with Teprotumumab for Thyroid Eye Disease
• Teprotumumab for patients with active thyroid eye disease: pooled data analysis, subgroup analyses, andoff-treatment follow-up results
• Thyroid Eye Disease, Teprotumumab, and Hearing Loss: An Evolving Role for Otolaryngologists
• Audiology findings in patients with teprotumumab associated otologic symptoms
• Graves’ Disease: Patient Information
• Teprotumumab for the Treatment of Active Thyroid Eye Disease

Uveitis

• Efficacy and Safety of Suprachoroidal CLS-TA for Macular Edema Secondary to Noninfectious Uveitis: Phase 3 Randomized Trial (PEACHTREE)
• Real-Life Efficacy, Safety, and Use of Dexamethasone Intravitreal Implant in Posterior Segment Inflammation Due to Non-infectious Uveitis (LOUVRE 2 Study)
• Epidemiology and Risk Factors in Non-infectious Uveitis: A Systematic Review
• OCT Anatomic and Temporal Biomarkers in Uveitic Macular Edema
• Visual Acuity in Retinal Vein Occlusion, Diabetic, and Uveitic Macular Edema: Central Subfield Thickness and Ellipsoid Zone Analysis
• Fluocinolone Acetonide Intravitreal Implant for Treating Recurrent Non-infectious Uveitis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
• Preparing for Your Appointment – Patient Handout

Vitreoretinal Surgery

• Preparing for a Vitrectomy – Patient Handout

Pain Management

• CDC Clinical Practice Guideline for Prescribing Opioids for Pain — United States, 2022

Substance Use Disorders

• Medication-Assisted Treatment Using Buprenorphine

Anesthesia

• Statement on Practice Recommendations for Pediatric Anesthesia
• Sugammadex and recurarization in an infant
  
• Sugammadex for reversal of neuromuscular blockade in pediatric patients: Results from a phase IV randomized study
• Sugammadex: Applications in Pediatric Critical Care
• Smart Tots

Gastroenterology

• Cryptosporidiosis
• Giardiasis
• For Parents: Treating Pediatric Dehydration
• Swimming Pool Hygiene
• Children’s Health
• GI Kids

Psychiatry

• CDC what is ADHD?
• Symptoms of ADHD
• Diagnosing ADHD

Respiratory Syncytial Virus (RSV)

• CDC: FAQs About RSV Immunization with mAb for Children ≤ 19 Months
• JAMA: Trends in Age and Disease Severity in Children Hospitalized With RSV Infection Before and During the COVID-19 Pandemic
• AAP Nirsevimab Administration Visual Guide
• Bivalent Prefusion F Vaccine in Pregnancy to Prevent RSV Illness in Infants
• ACOG RSV Prevention Practice Advisory
• For Healthcare Providers: RSV Prevention Information
• MMWR: ACIP Recommendations for Nirsevimab
• MMWR: ACIP Recommendations for Maternal RSV Vaccine
• Nirsevimab Prescribing Information
• Maternal RSV Vaccine Prescribing Information
• Respiratory syncytial virus infection during infancy and asthma during childhood in the USA (INSPIRE)
• Infants Admitted to US Intensive Care Units for RSV Infection During the 2022 Seasonal Peak
• CDC Recommendations for RSV Prevention
• Phase 3 MELODY: Nirsevimab for Prevention of RSV in Term and Late-Preterm Infants
• 2024 Recommended Child and Adolescent Immunization Schedule for Ages 18 Years or Younger
• Palivizumab Prophylaxis in Infants and Young Children at Increased Risk of Hospitalization for Respiratory Syncytial Virus Infection
• CDC: RSV Vaccination for Pregnant People
• Patient Brochure: RSV in Infants and Young Children

Vaccine-preventable Diseases: General

• Pediatric Vaccination – Information for Parents

Vaccine-preventable Diseases: Influenza

• Flu: A Guide for Parents
• Frequently Asked Influenza (Flu) Questions: 2024-2025 Season
• No More Excuses: You Need a Flu Vaccine
• Make a Strong Influenza Vaccine Recommendation
• Influenza Activity in the United States during the 2023–2024 Season and Composition of the 2024–2025 Influenza Vaccine
• Influenza vaccines: the potential benefits of cell-culture isolation and manufacturing
• Clinical and Economic Outcomes Associated with Cell-Based Quadrivalent Influenza Vaccine vs. Standard-Dose Egg-Based Quadrivalent Influenza Vaccines during the 2018–19 Influenza Season in the United States
• A real-world study evaluating the relative vaccine effectiveness of a cell-based quadrivalent influenza vaccine compared to egg-based quadrivalent influenza vaccine in the US during the 2017–18 influenza season – ScienceDirect
• Recommendations for Prevention and Control of Influenza in Children, 2022-2023
• Recommendations for Prevention and Control of Influenza in Children, 2022–2023

Vaccine-preventable Diseases: Human Papillomavirus (HPV)

• HPV vaccine promotion: Snapshot of two health departments during the COVID-19 pandemic
• Understanding primary care physician perspectives on recommending HPV vaccination and addressing vaccine hesitancy
• Top 10 Tips for HPV Vaccination Success
• CDC: ACIP’s HPV Vaccination Recommendations
• CDC: Talking to Parents about HPV Vaccine
• Pediatric Vaccination – Information for Parents
• CDC Resources, Education & References for HPV Vaccination
• Human Papillomavirus Vaccination: ACOG Committee Opinion Vaccination
• HPV Vaccination: What Everyone Should Know
• CDC HPV Vaccine Recommendations
• Standing Order for HPV Vaccine
• Centers for Disease Control and Prevention HPV Vaccine Recommendations
• Recommended Immunization Schedule for Persons Aged 0 Through 18 Years (United States, 2024) – Educational Tool for Clinicians and Nurses
• Why Are Childhood Vaccines So Important? – Educational Tool for Parents

Biosimilars

• State Laws and Legislation Related to Biologic Medications and Substitution of Biosimilars

Binge Eating Disorder (BED)

• Definition & Facts for Binge Eating Disorder – NIH Patient Education
• Binge Eating Disorder (BED) – A Comorbid Conundrum
• Binge Eating Disorder Resources

Bipolar Disorder

• Efficacy and Safety of Lumateperone for Major Depressive Episodes Associated With Bipolar I or Bipolar II Disorder: A Phase 3 Randomized Placebo-Controlled Trial
• Evaluating lurasidone as a treatment option for bipolar disorder
• Bipolar Disorder Diagnosis and Treatment for Patients

Depression

• National Alliance on Mental Health (NAMI) – Depression
• NIH Information and Resources on Depression (Including Perinatal Depression)
• U.S Preventive Services Task Force: Perinatal Depression – Preventive Interventions
• CDC Patient Information and Resources: Depression During and After Pregnancy
• Feeling sad after your baby is born? Video from the American Academy of Pediatrics
• Perinatal depression: A review
• Development of neuroactive steroids for the treatment of postpartum depression
• Patient-Specific Considerations, the GABA Pathway, and New Clinical Trial Data on Neuroactive Steroids in MDD and PPD
• Brexanolone Prescribing Information
• Safety of Brexanolone in Adults with Postpartum Depression: Postmarketing Surveillance Data
• GABAkines – Advances in the discovery, development, and commercialization of positive allosteric modulators of GABA_A receptors
• Effect of brexanolone on depressive symptoms, anxiety, and insomnia in women with postpartum depression: Pooled analyses from 3 double-blind, randomized, placebo-controlled clinical trials in the HUMMINGBIRD clinical program
• Zuranolone for the Treatment of Adults With Major Depressive Disorder: A Randomized, Placebo-Controlled Phase 3 Trial
• Zuranolone in Major Depressive Disorder: Results From MOUNTAIN-A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial
• Effect of Zuranolone vs Placebo in Postpartum Depression: A Randomized Clinical Trial
• Effect of Zuranolone on Concurrent Anxiety and Insomnia Symptoms in Women With Postpartum Depression
• Allopregnanolone in postpartum depression: Role in pathophysiology and treatment
• BPRS Brief Psychiatric Rating Scale
• PHQ-9 Quick Depression Assessment
• Montgomery-Asberg Depression Rating Scale
• Edinburgh Postnatal Depression Scale
• Depression – stopping your medicine – Patient Handout
• Major Depressive Disorder – Patient Handout
• What are the Causes of Depression? – Patient Handout

Parkinson’s Disease Psychosis

• QTc Interval Prolongation with Therapies Used to Treat Patients with Parkinson’s Disease Psychosis: A Narrative Review
• Depression in Patients with Parkinson’s Disease: Current Understanding of its Neurobiology and Implications for Treatment

Schizophrenia

• Schizophrenia educational resources
• Emerging Treatments in Schizophrenia
• Beyond Dopamine Receptor Antagonism: New Targets for Schizophrenia Treatment and Prevention
• A Non–D2-Receptor-Binding Drug for the Treatment of Schizophrenia
• Safety and effectiveness of ulotaront (SEP-363856) in schizophrenia: results of a 6-month, open-label extension study
• Trace Amine-Associated Receptor 1 (TAAR1): Molecular and Clinical Insights for the Treatment of Schizophrenia and Related Comorbidities
• Xanomeline–Trospium for Schizophrenia
• Muscarinic Cholinergic Receptor Agonist and Peripheral Antagonist for Schizophrenia
• Support Groups and Supportive Resources – Patient Handout
• Approach to Schizophrenia Management At-A-Glance – Patient Handout
• Schizophrenia: Recognizing the Symptoms and Getting Treatment – Patient Handout

Substance Use Disorders

• Providers’ Clinical Support System for Opioid Therapies (PCSS-O): Educational Resources
• Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction
• Opioid Treatment Program (OTP) Certification
• Medication Assisted Treatment (MAT) Certification

Tardive Dyskinesia (TD)

• Abnormal Involuntary Movement Scale exam
• Valbenazine Prescribing Information

Interstitial Lung Disease (ILD)

• PH-ILD Patient Resources
• Pulmonary Fibrosis Foundation Educational Resources
• Inhaled Treprostinil in Pulmonary Hypertension Due to Interstitial Lung Disease
• Inhaled treprostinil and forced vital capacity in patients with interstitial lung disease and associated pulmonary hypertension: a post-hoc analysis of the INCREASE study
• The Trouble With Group 3 Pulmonary Hypertension in Interstitial Lung DiseaseDilemmas in Diagnosis and the Conundrum of Treatment
• Pulmonary hypertension in interstitial lung disease: screening, diagnosis and treatment
• Diagnosis and Management of Pulmonary Hypertension in the Modern Era: Insights from the 6th World Symposium
• Impact of lung morphology on clinical outcomes with riociguat in patients with pulmonary hypertension and idiopathic interstitial pneumonia: A post hoc subgroup analysis of the RISE-IIP study
• A Randomized, Double-Blind, Placebo-Controlled Study of Pulsed, Inhaled Nitric Oxide in Subjects at Risk of Pulmonary Hypertension Associated With Pulmonary Fibrosis
• Inhaled Treprostinil: Prescribing Information
• Nintedanib Prescribing Information
• Pirfenidone Prescribing Information
• Diagnosis of Hypersensitivity Pneumonitis in Adults: An Official ATS/JRS/ALAT Clinical Practice Guideline
• Progressive fibrosing interstitial lung disease: clinical uncertainties, consensus recommendations, and research priorities
• Pulmonary Fibrosis Foundation Patient Education Materials
• Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial
• Utility of a Molecular Classifier as a Complement to High-Resolution Computed Tomography to Identify Usual Interstitial Pneumonia
• Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial

Interstitial Lung Disease (ILD): Sarcoidosis

• ERS clinical practice guidelines on treatment of sarcoidosis

Non-Tuberculous Mycobacteria

• Learn about NTM Lung Disease
• “INSIGHT” A Patient’s Perspective on NTM
• CDC Clinician Resources on NTM Infection
• Treatment of Nontuberculous Mycobacterial Pulmonary Disease: An Official ATS/ERS/ESCMID/IDSA Clinical Practice Guideline
• NORD Nontuberculous Mycobacterial Lung Disease Patient and Family Resources

Pulmonary Hypertension

• Inhaled Treprostinil Dosage in Pulmonary Hypertension Associated With Interstitial Lung Disease and Its Effects on Clinical Outcome
• Efficacy of Inhaled Treprostinil on Multiple Disease Progression Events in Patients with Pulmonary Hypertension due to Parenchymal Lung Disease in the INCREASE Trial
• Long-term inhaled treprostinil for pulmonary hypertension due to interstitial lung disease: INCREASE open-label extension study
• Clinical significance of pulmonary hypertension in interstitial lung disease: A consensus statement from the Pulmonary Vascular Research Institute’s innovative drug development initiative-Group 3 pulmonary hypertension
• Screening Strategies for Pulmonary Hypertension in Patients With Interstitial Lung Disease: A Multidisciplinary Delphi Study
• Bridging Specialties: ILD Clinician Toolkit
• Pulmonary Fibrosis Foundation: PH-ILD for Patients
• Pulmonary Fibrosis Foundation: PH-ILD for Healthcare providers
• 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension
• Pulmonary Hypertension Association: Patient Resources
• PAH Risk Score Calculators
• Clinical application of risk assessment in PAH: Expert center APRN recommendations
• Risk Stratification in Pulmonary Arterial Hypertension, Update and Perspectives
• American Lung Association PAH Patient Resources
• Phase 3 Trial of Sotatercept for Treatment of Pulmonary Arterial Hypertension
• Novel Drugs for the Treatment of Pulmonary Arterial Hypertension: Where Are We Going?
• Novel and emerging therapies in pulmonary arterial hypertension

General

• Upadacitinib Prescribing Information
• Risankizumab Prescribing Information
• Guselkumab Prescribing Information
• ACR COVID-19 Vaccine Clinical Guidance Summary for Patients with Rheumatic and Musculoskeletal Diseases

Biosimilars

• Biosimilars: More Treatment Options Are on the Way
• FDA’s Overview of the Regulatory Guidance for the Development and Approval of Biosimilar Products in the US

Gout

• ASN Kidney Week 2023 Abstracts
• EULAR 2024 Abstract Book
• ACR Convergence 2024 Abstracts
• Alliance for Gout Awareness Resources
• Gout Patient Education & Resources
• 2020 American College of Rheumatology Guideline for the Management of Gout
• What’s new on the front-line of gout pharmacotherapy?
• A glance into the future of gout
• PROTECT: Pegloticase efficacy and safety in kidney transplant recipients; results of the phase IV, open-label clinical trial
• RECIPE: Reducing Immunogenicity of Pegloticase With Concomitant Use of Mycophenolate Mofetil in Patients With Refractory Gout: A Phase II, Randomized, Double-Blind, Placebo-Controlled Trial
• MIRROR RCT: A Randomized, Placebo-Controlled Study of Methotrexate to Increase Response Rates in Patients with Uncontrolled Gout Receiving Pegloticase: Primary Efficacy and Safety Findings
• Expert Opinion on Pegloticase with Concomitant Immunomodulatory Therapy in the Treatment of Uncontrolled Gout to Improve Efficacy, Safety, and Durability of Response
• Pegloticase in Combination With Methotrexate in PatientsWith Uncontrolled Gout: A Multicenter, Open-label Study(MIRROR)
• Impact of Uncontrolled Gout on Quality of Life and Importance of Open Dialogue With Patients
• Pegloticase Prescribing Information
• Pegloticase treatment of chronic refractory gout: Update on efficacy and safety
• Gout Patient fact Sheet

IgG4-related disease (IgG4-RD)

• 2019 ACR/EULAR Classification Criteria for IgG4-Related Disease
• (ACR) Information on IgG4-Related Disease: What they are, Getting Diagnosed, Treatment Options, and More
• MITIGATE – Phase 3 Clinical Trial: Efficacy and Safety of Inebilizumab in IgG4-Related Disease

Immune-mediated adverse reactions

• Treatment of immune checkpoint inhibitor-induced inflammatory arthritis.
• Immune-related Adverse Events Associated with Cancer Immunotherapy: A Review for the Practicing Rheumatologist

Psoriatic Arthritis

• Joint AAD–NPF Guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures
• Psoriatic Arthritis – Disease Primer
• Comparative effectiveness of guselkumab in psoriatic arthritis: results from systematic literature review and network meta-analysis
• JAK inhibitors and psoriatic arthritis: A systematic review and meta-analysis
• 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis
• EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update
• Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFα inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial
• Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial

Spondyloarthritis

• ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update
• JAK1 selective inhibitors for the treatment of spondyloarthropathies
• Axial spondyloarthritis: new advances in diagnosis and management
• TYK2 as a therapeutic target in the treatment of autoimmune and inflammatory diseases
• From Science to Success? Targeting Tyrosine Kinase 2 in Spondyloarthritis and Related Chronic Inflammatory Diseases
• Recognizing Axial Spondyloarthritis: A Guide for Primary Care
• Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, placebo-controlled study
• Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement
• JAK Inhibitors for Axial Spondyloarthritis: What does the Future Hold?
• Pain in Axial Spondyloarthritis: More to It Than Just Inflammation
• Spondylitis Association of America: Resources and Support
• Spondyloarthritis Patient Fact Sheet
• What Is Axial Spondyloarthritis (AxSpA)?
• Recommendations for the Treatment of Ankylosing Spondylitis
• Achievement of Remission Endpoints with Secukinumab Over 3 Years in Active Ankylosing Spondylitis: Pooled Analysis of Two Phase 3 Studies
• Secukinumab in patients with psoriatic arthritis and axial manifestations: results from the double-blind, randomised, phase 3 MAXIMISE trial
• Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial

Juvenile Idiopathic Arthritis (JIA)

• ACR Update of Recommendations to the Treatment of JIA
• What is JIA? – Patient Handout

Lupus

• Phase III/IV, Randomized, Fifty-Two-Week Study of the Efficacy and Safety of Belimumab in Patients of Black African Ancestry With Systemic Lupus Erythematosus
• Safety and efficacy of intravenous belimumab in children with systemic lupus erythematosus: results from a randomised, placebo-controlled trial
• Long-term outcomes in systemic lupus erythematosus: trends over time and major contributors
• 2019 Update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis
• 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus
• Lupus Foundation of American Caregiver Toolkit
• Patient Fact Sheet: Lupus
• Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis
• Phase 3 AURORA study of voclosporin versus standard of care in lupus nephritis
• Belimumab prescribing information
• Voclosporin prescribing information

Rheumatoid Arthritis (RA)

• EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update
• 2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis
• RA and Vaccinations
• The Purple Book for Biosimilars
• RA Overview (for Patients)
• RA Treatment (for Patients)
• FDA Information on Biosimilars (for Patients)

Systemic Sclerosis

• Understanding Scleroderma: National Scleroderma Foundation Patient Education
• 2013 Classification Criteria for Systemic Sclerosis: An American College of Rheumatology/European League Against Rheumatism Collaborative Initiative

Vasculitis

ANCA-Associated Vasculitis

• EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update
• 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Antineutrophil Cytoplasmic Antibody–Associated Vasculitis
• ANCA-Associated Vasculitis
• EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis

Eosinophilic Granulomatosis With Polyangiitis (EGPA)

• Evidence-Based Guideline for the diagnosis and management of eosinophilic granulomatosis with polyangiitis
• Mepolizumab for Eosinophilic Granulomatosis With Polyangiitis: A European Multicenter Observational Study
• Sequential rituximab and mepolizumab in eosinophilic granulomatosis with polyangiitis (EGPA): a European multicentre observational study
• Vasculitis Foundation: Eosinophilic Granulomatosis With Polyangiitis
• NIH Genetic and Rare Diseases Information Center: Eosinophilic Granulomatosis With Polyangiitis
• National Organization for Rare Disorders: Churg Strauss Syndrome

Giant Cell Arteritis

• Giant Cell Arteritis – Fast Facts for Patients
• Giant Cell Arteritis – Vasculitis Foundation
• ACR/EULAR Classification of Giant Cell Arteritis
• Giant Cell Arteritis

Menopause

• Patient Resource: Mobile-friendly “Swiper” Tool
• Menopause Society for Clinicians
• Menopause Society for Women
• Patient Resource: Deciding About Hormone Therapy Use
• Patient Resource: Vaginal Dryness
• Patient Resource: Nonhormone Treatments for Hot Flashes and Night Sweats
• “The 2023 Nonhormone Therapy Position Statement of The North American Menopause Society”
• Understanding Attitudes, Beliefs, and Behaviors Surrounding Menopause Transition
• Disparities in Reproductive Aging and Midlife Health between Black and White women: The Study of Women’s Health Across the Nation (SWAN)
• A review of African American women’s experiences in menopause